Skip to main content

Advertisement

SpringerLink
Log in

The Clinical Features of Myositis-Associated Autoantibodies: a Review

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases traditionally defined by clinical manifestations including skeletal muscle weakness, skin rashes, elevated skeletal muscle enzymes, and neurophysiological and/or histological evidence of muscle inflammation. Patients with myositis overlap can develop other features including parenchymal lung disease, inflammatory arthritis, gastrointestinal manifestations and marked constitutional symptoms. Although patients may be diagnosed as having polymyositis (PM) or dermatomyositis (DM) under the IIM spectrum, it is quite clear that disease course between subgroups of patients is different. For example, interstitial lung disease may predominate in some, whereas cutaneous complications, cancer risk, or severe refractory myopathy may be a significant feature in others. Therefore, tools that facilitate diagnosis and indicate which patients require more detailed investigation for disease complications are invaluable in clinical practice. The expanding field of autoantibodies (autoAbs) associated with connective tissue disease (CTD)-myositis overlap has generated considerable interest over the last few years. Using an immunological diagnostic approach, this group of heterogeneous conditions can be separated into a number of distinct clinical phenotypes. Rather than diagnose a patient as simply having PM, DM or overlap CTD, we can define syndromes to differentiate disease subsets that emphasise clinical outcomes and guide management. There are now over 15 CTD-myositis overlap autoAbs found in patients with a range of clinical manifestations including interstitial pneumonia, cutaneous disease, cancer-associated myositis and autoimmune-mediated necrotising myopathy. This review describes their diagnostic utility, potential role in disease monitoring and response to treatment. In the future, routine use of these autoAb will allow a stratified approach to managing this complex set of conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347

    Article  CAS  PubMed  Google Scholar 

  2. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407

    Article  CAS  PubMed  Google Scholar 

  3. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, Sato T, Kiuchi T, Ohashi Y (1995) Classification criteria for polymyositis and dermatomyositis. J Rheumatol 22(4):668–674

    CAS  PubMed  Google Scholar 

  4. Gunawardena H, Betteridge ZE, McHugh NJ (2009) Myositis specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 48(6):607–612

    Article  CAS  PubMed  Google Scholar 

  5. Tansley S, Gunawardena H (2014) The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol 47(3):264–273

    Article  PubMed  Google Scholar 

  6. Kang EH, Kuwana M, Okazaki Y, Lee EY, Lee YJ, Lee EB et al (2014) Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients. Mod Rheumatol 24(6):945–948

    Article  CAS  PubMed  Google Scholar 

  7. Ronnelid J, Barbasso Helmers S, Storfors H, Grip K, Ronnblom L, Franck-Larsson K et al (2009) Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 9(1):58–61

    Article  PubMed  CAS  Google Scholar 

  8. Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K et al (2014) The multicenter study of a New assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS ONE 9(1), e85062

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Aggarwal R, Oddis CV, Goudeau D, Fertig N, Metes I, Stephens C et al. (2014) Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology Dec 17 pii: keu436 [Epub ahead of print]

  10. Hane H, Muro Y, Watanabe K, Ogawa Y, Sugiura K, Akiyama M (2014) Establishment of an ELISA to detect anti-glycyl-tRNA synthetase antibody (anti-EJ), a serological marker of dermatomyositis/polymyositis and interstitial lung disease. Clin Chim Acta 431:9–14

    Article  CAS  PubMed  Google Scholar 

  11. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60(7):2193–2200

    Article  CAS  PubMed  Google Scholar 

  12. Aggarwal R, Oddis CV, Goudeau D, Fertig N, Metes I, Stephens C et al (2014) Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation. Rheumatology 53(3):433–437

    Article  CAS  PubMed  Google Scholar 

  13. Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A et al (2012) Anti-TIF1 antibodies (antip155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis 71(6):993–996

    Article  CAS  PubMed  Google Scholar 

  14. Ishikawa A, Muro Y, Sugiura K, Akiyama M (2012) Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology 51(7):1181–1187

    Article  CAS  PubMed  Google Scholar 

  15. Muro Y, Sugiura K, Akiyama M (2013) A new ELISA for dermatomyositis autoantibodies: rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement. Clin Dev Immunol 2013:856815

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Mammen AL, Chung T, Christopher-Stine L (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin associated autoimmune myopathy. Arthritis Rheum 63(3):713–721

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Musset L, Miyara M, Benveniste O, Charuel J-L, Shikhman A, Boyer O et al (2014) Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies. Int J Immunol Res 2014:405956

    Google Scholar 

  18. Drouot L, Allenbach Y, Jouen F, Charuel J-L, Martinet JRM, Meyer A et al (2014) Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3- methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther 16(1):1–11

    Article  Google Scholar 

  19. Friedman AW, Targoff IN, Arnett FC (1996) Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 26(1):459–467

    Article  CAS  PubMed  Google Scholar 

  20. Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK et al (2009) Clinical profile of anti-PL-12 autoantibody: cohort study and review of the literature. Chest 135(6):1550–1556

    Article  CAS  PubMed  Google Scholar 

  21. Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35–42

    Article  CAS  PubMed  Google Scholar 

  22. Debray MP, Borie R, Revel MP, Naccache JM, Khalil A, Toper C et al (2015) Interstitial lung disease in anti-synthetase syndrome: initial and follow up CT findings. Eur J Radiol 84(3):516–523

    Article  PubMed  Google Scholar 

  23. Fischer A, Brown KK (2015) Interstitial lung disease in undifferentiated forms of connective tissue disease. Arthritis Care Res 67(1):4–11

    Article  Google Scholar 

  24. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, Walport MJ (1990) Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77(282):1019–1038

    Article  CAS  PubMed  Google Scholar 

  25. Hallowell RW, Ascherman DP, Danoff SK (2014) Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med 35(2):239–248

    Article  PubMed  Google Scholar 

  26. Hallowell RW, Danoff SK (2014) Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: recent advances. Curr Opin Rheumatol 26(6):684–689

    Article  CAS  PubMed  Google Scholar 

  27. Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S et al (2011) Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med 105(8):1238–1472

    Article  PubMed  Google Scholar 

  28. Schneider F, Yousem SA, Bi D, Gibson KF, Oddis CV, Aggarwal R (2014) Pulmonary pathologic manifestations of anti-glycl-tRNA synthetase (anti-EJ)- related inflammatory myopathy. J Clin Pathol 67(8):678–683

    Article  PubMed  Google Scholar 

  29. Marie I, Josse S, Decaux O, Diot E, Landron C, Roblot P et al (2013) Clinical manifestations and outcome of anti-PL7 positive patients with anti-synthetase syndrome. Eur J Intern Med 24(5):474–479

    Article  CAS  PubMed  Google Scholar 

  30. Johnson C, Connors GR, Oaks J, Han S, Truong A, Richardson B et al (2014) Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med 108(10):1542–1548

    Article  CAS  PubMed  Google Scholar 

  31. Marie I, Josse S, Decaux O, Dominique S, Landron C, Roblot P et al (2013) Outcome of anti-PL12 positive patients with antisynthetase syndrome. Presse Med 42(6):e153–e158

    Article  PubMed  Google Scholar 

  32. Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11(10):739–745

    Article  CAS  PubMed  Google Scholar 

  33. Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M et al (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 8(4), e60442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Lefevre G, Meyer A, Launay D, Machelart I, DeBandt M, Michaud J et al (2014) Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. Rheumatology 27

  35. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52(5):1571–1576

    Article  CAS  PubMed  Google Scholar 

  36. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65(1):25–34

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C et al (2014) Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 16(4):R138

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32(6):891–897

    PubMed  Google Scholar 

  39. Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, Juárez C (2014) Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. Int J Immunol Res 2014:290797

    Google Scholar 

  40. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K et al (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 49(9):1713–1719

    Article  CAS  PubMed  Google Scholar 

  41. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51(9):1563–1567

    Article  CAS  PubMed  Google Scholar 

  42. Chaisson NF, Paik J, Orbai AM, Casciola-Rosen L, Fiorentino D, Danoff S, Rosen A (2012) A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore) 91(4):220–228

    Article  Google Scholar 

  43. Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, Christopher-Stine L (2013) Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 65(8):1307–1315

    Article  CAS  Google Scholar 

  44. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T (2011) Anti-melanoma differentiation -associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 158(4):675–677

    Article  CAS  PubMed  Google Scholar 

  45. Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K et al (2014) Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology

  46. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr (2009) Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 60(4):1112–1118

    Article  PubMed  Google Scholar 

  47. Koschik RW 2nd, Fertig N, Lucas MR, Domsic RT, Medsger TA Jr (2012) Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 30(2):S12–S16

    PubMed  Google Scholar 

  48. D’Aoust J, Hudson M, Tatibouet S, Wick J, Canadian Scleroderma Research Group, Mahler M, Baron M, Fritzler MJ (2014) Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheum 66(6):1608–1615

    Article  CAS  Google Scholar 

  49. Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF (2010) Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol 37(5):1000–1009

    Article  CAS  PubMed  Google Scholar 

  50. Hanke K, Brückner CS, Dähnrich C, Huscher D, Komorowski L, Meyer W et al (2009) Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 11(1):R22

    Article  PubMed  PubMed Central  Google Scholar 

  51. Guillen-Del Castillo A, Pilar Simeón-Aznar C, Fonollosa-Pla V, Alonso-Vila S, Reverte-Vinaixa MM, Muñoz X et al (2014) Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. Semin Arthritis Rheum 44(3):331–337

    Article  PubMed  Google Scholar 

  52. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, Leroy EC, Fritzler MJ (1996) Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 39(7):1151–1160

    Article  CAS  PubMed  Google Scholar 

  53. Tormey VJ, Bunn CC, Denton CP, Black CM (2001) Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 40(10):1157–1162

    Article  CAS  PubMed  Google Scholar 

  54. Kaji K, Fertig N, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y et al (2014) Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res 66(4):575–584

    Article  CAS  Google Scholar 

  55. Olazagasti JM, Baez PJ, Wetter DA, Ernste FC (2015) Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol 16(2):89–98

    Article  PubMed  Google Scholar 

  56. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66(10):1345–1349

    Article  PubMed  PubMed Central  Google Scholar 

  57. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study Group; International Myositis Collaborative Study Group (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–3689

    Article  CAS  PubMed  Google Scholar 

  58. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y et al (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 46(1):25–28

    Article  CAS  PubMed  Google Scholar 

  59. Trallero-Araguás E, Labrador-Horrillo M, Selva-O’Callaghan A, Martínez MA, Martínez-Gómez X, Palou E, Rodriguez-Sanchez JL, Vilardell-Tarrés M (2010) Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 89(1):47–52

    Article  CAS  Google Scholar 

  60. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M et al (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64(2):513–522

    Article  CAS  PubMed  Google Scholar 

  61. Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O’Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo M, Grau-Junyent JM, Vilardell-Tarrés M (2012) Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 64(2):523–532

    Article  PubMed  CAS  Google Scholar 

  62. Selva-O’Callaghan A, Trallero-Araguás E, Grau-Junyent JM, Labrador-Horrillo M (2010) Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 22(6):627–632

    Article  PubMed  Google Scholar 

  63. Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol 72(3):449–455

    Article  PubMed  PubMed Central  Google Scholar 

  64. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 65(11):2954–2962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71(5):710–713

    Article  CAS  PubMed  Google Scholar 

  66. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H et al (2008) Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 47(3):324–328

    Article  CAS  PubMed  Google Scholar 

  67. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A et al (2008) Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 87(2):70–86

    Article  Google Scholar 

  68. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV (2009) Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 36(11):2547–2551

    Article  CAS  PubMed  Google Scholar 

  69. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE et al (2009) Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60(6):1807–1814

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, McHugh NJ, Juvenile Dermatomyositis Research Group (2014) Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology 53(12):2204–2208

    Article  PubMed  PubMed Central  Google Scholar 

  71. Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150(7):724–729

    Article  PubMed  PubMed Central  Google Scholar 

  72. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M et al (2012) Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14(2):R97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Sugiura K, Muro Y, Akiyama M (2012) Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis. J Am Acad Dermatol 67(4):e167–e168

    Article  CAS  PubMed  Google Scholar 

  74. Shah AA, Casciola-Rosen L, Rosen A (2015) Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheum 67(2):317–326

    Article  CAS  Google Scholar 

  75. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, McHugh NJ, UK Adult Onset Myositis Immunogenetic Collaboration (2009) Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 68(10):1621–1625

    Article  CAS  PubMed  Google Scholar 

  76. Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A (2012) Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 384(1–2):128–134

    Article  CAS  PubMed  Google Scholar 

  77. Muro Y, Sugiura K, Akiyama M (2013) Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity 46(4):279–284

    Article  CAS  PubMed  Google Scholar 

  78. Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K (2014) Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 13(12):1211–1219

    Article  CAS  PubMed  Google Scholar 

  79. Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F et al (2013) Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 72(1):151–153

    Article  PubMed  Google Scholar 

  80. Targoff IN, Reichlin M (1985) The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 28(7):796–803

    Article  CAS  PubMed  Google Scholar 

  81. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW, International Myositis Collaborative Study Group (2003) Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 48(8):2285–2293

    Article  PubMed  Google Scholar 

  82. Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger TA Jr, Reveille JD, Arnett FC, Targoff IN, Miller FW (2009) Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 60(8):2499–2504

    Article  PubMed  PubMed Central  Google Scholar 

  83. Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramírez R, Jara LJ, Saavedra MA et al (2013) Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther 4;15(2):R48

    Article  CAS  Google Scholar 

  84. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW, Childhood Myositis Heterogeneity Collaborative Study Group (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(4):223–243

    Article  CAS  Google Scholar 

  85. Brown DA, Simoni RD (1984) Biogenesis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, an integral glycoprotein of the endoplasmic reticulum. Proc Natl Acad Sci U S A 81(6):1674–1678

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Olender EH, Simon RD (1992) The intracellular targeting and membrane topology of 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem 25;267(6):4223–4235

    Google Scholar 

  87. Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J et al (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65(12):1635–1638

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Targoff IN, Johnson AE, Miller FW (1990) Antibody to signal recognition particle in polymyositis (1990). Arthritis Rheum 33(9):1361–1370

    Article  CAS  PubMed  Google Scholar 

  89. Hengstman GJ, Brouwer R, Egberts WT, Seelig HP, Jongen PJ, van Venrooij WJ, van Engelen BG (2002) Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 249(1):69–75

    Article  CAS  PubMed  Google Scholar 

  90. Basnayake SK, Blumbergs P, Tan JA, Roberts-Thompson PJ, Limaye V (2015) Inflammatory myopathy with anti-SRP antibodies: case series of a South Australian cohort. Clin Rheumatol 34(3):603–608

    Article  PubMed  Google Scholar 

  91. Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73(4):420–428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Suzuki S, Hayashi YK, KuwanaM TR, Suzuki N, Nishino I (2012) Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol 69(6):728–732

    Article  PubMed  Google Scholar 

  93. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40(3):567–572

    Article  PubMed  Google Scholar 

  94. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL (2010) A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62(9):2757–2766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, Zachary AA (2012) Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res 64(8):1233–1237

    CAS  Google Scholar 

  96. Limaye V, Bundell C, Hollingsworth P, Rojana-Udomsart A, Mastaglia F, Blumbergs P, Lester S (2014) Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve. doi:10.1002/mus.24541

    Google Scholar 

  97. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 21;359(8):789–799

    Google Scholar 

  98. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA (2010) Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41(2):185–190

    CAS  PubMed  Google Scholar 

  99. Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, Lloyd TE, Mammen AL (2012) Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 64(12):4087–4093

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP (2007) Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 56(9):3125–3131

    Article  CAS  PubMed  Google Scholar 

  101. Sato S, Kuwana M, Fujita T, Suzuki Y (2013) Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23(3):496–502

    Article  CAS  PubMed  Google Scholar 

  102. Muro Y, Sugiura K, Hoshino K, Akiyama M (2012) Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology 51:800–804

    Article  CAS  PubMed  Google Scholar 

  103. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, Oddis CV (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73(1):227–232

    Article  PubMed  Google Scholar 

  104. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49(3):433–440

    Article  CAS  Google Scholar 

  105. Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 15(8):CD003643

    Google Scholar 

  106. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S et al (2007) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 46(1):124–130

    Article  CAS  PubMed  Google Scholar 

  107. Morganroth PA, Kreider ME, Werth VP (2010) Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res 62(10):1496–1501

    Article  Google Scholar 

  108. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40(5):640–646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV (2005) Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 52(8):2439–2446

    Article  CAS  PubMed  Google Scholar 

  110. Labirua-Iturburu A, Selva-O’Callaghan A, Martínez-Gómez X, Trallero-Araguás E, Labrador-Horrillo M, Vilardell-Tarrés M (2013) Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 31(3):436–439

    PubMed  Google Scholar 

  111. Cavagna L, Caporali R, Abdì-Alì L, Dore R, Meloni F, Montecucco C (2013) Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol 40(4):484–492

    Article  CAS  PubMed  Google Scholar 

  112. Kurita T, Yasuda S, Amengual O, Atsumi T (2015) The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus 24(1):3–9

    Article  CAS  PubMed  Google Scholar 

  113. Muro Y, Sugiura K, Akiyama M (2013) Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol 32(3):395–398

    Article  PubMed  Google Scholar 

  114. Tanaka F, Origuchi T, Migita K, Tominaga M, Kawakami A, Kawabe Y, Eguchi K (2000) Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 39(5):428–430

    Article  CAS  PubMed  Google Scholar 

  115. Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, Amano K, Takeuchi T (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32(9):1719–1726

    CAS  PubMed  Google Scholar 

  116. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52(2):601–607

    Article  CAS  PubMed  Google Scholar 

  117. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 62(9):1328–1334

    Article  CAS  Google Scholar 

  118. Couderc M, Gottenberg JE, Mariette X, Hachulla E, Sibilia J, Fain O et al (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology 50(12):2283–2289

    Article  CAS  PubMed  Google Scholar 

  119. Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A et al (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 38(7):1436–1440

    Article  CAS  PubMed  Google Scholar 

  120. Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 50(12):2206–2213

    Article  CAS  PubMed  Google Scholar 

  121. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum 66(3):740–749

    Article  CAS  Google Scholar 

  123. Marie I, Dominique S, Janvresse A, Levesque H, Menard JF (2012) Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 106(4):581–587

    Article  CAS  PubMed  Google Scholar 

  124. Clottu A, Laffitte E, Prins C, Chizzolini C (2012) Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis. Dermatology 225(4):376–380

    Article  PubMed  Google Scholar 

  125. Nalotto L, Iaccarino L, Zen M, Gatto M, Borella E, Domenighetti M, Punzi L, Doria A (2013) Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res 56(2–3):362–370

    Article  CAS  PubMed  Google Scholar 

  126. Muñoz-Beamud F, Isenberg DA (2014) Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol 31(6):896–903

    Google Scholar 

  127. Unger L, Kampf S, Lüthke K, Aringer M (2014) Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology 53(9):1630–1638

    Article  PubMed  Google Scholar 

  128. Andersson H, Sem M, Lund MB, Aaløkken TM, Günther A, Walle-Hansen R, Garen T (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology

  129. Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M et al (2015) A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol 12:1–5

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical and Academic Rheumatology, North Bristol NHS Trust, Southmead Hospital, Bristol, BS10 5NB, UK

    Harsha Gunawardena

Authors
  1. Harsha Gunawardena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harsha Gunawardena.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gunawardena, H. The Clinical Features of Myositis-Associated Autoantibodies: a Review. Clinic Rev Allerg Immunol 52, 45–57 (2017). https://doi.org/10.1007/s12016-015-8513-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-015-8513-8

Keywords

Search

Navigation